Reactions 1704, p189 - 2 Jun 2018 Erythema multiforme: case report A 70-year-old woman developed erythema multiforme during treatment with imatinib for gastrointestinal stromal tumour (GIST) [route and time to reaction onset not stated]. The woman was diagnosed with GIST and a partial resection of the small intestine including tumour was performed. Subsequently, she started receiving adjuvant chemotherapy with imatinib 400 mg/day. However, she developed grade 4 erythema multiforme during the treatment. The woman’s imatinib treatment was discontinued for 15 days [outcome not stated]. Two years after the tumour resection, recurrence of peritoneal dissemination was observed. Hence, partial tumour resection was observed, and complete resection was performed within next 5 years after the surgery. Author comment: "Imatinib 400mg/day as adjuvant chemotherapy was administered. However administration was stopped for 15 days because of the Grade 4 erythema multiforme." Terada Y, et al. A Case of Small Intestinal GIST with Long-Term Survival after Tumor Resection for Repeated Peritoneal Recurrence. Gan to Kagaku Ryoho 44: 1521-1522, No. 12, Nov 2017 [Japanese; Summarised from an English abstract] - Japan 803322826 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera